Pharma Penny Stock On Watch $KPTI - Karyopharm Therapeutics Inc. #stockstowatch

Karyopharm Therapeutics Inc. (KPTI), is a clinical-stage pharmaceutical company that on Wednesday announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to selinexor, the Company’s first-in-class, oral SINE compound for the treatment of patients with diffuse large B-cell lymphoma. 

The FDA's Fast Track program facilitates the development of drugs intended to treat serious conditions and that have the potential to address unmet medical needs. “The receipt of Fast Track designation from the FDA for selinexor underscores the great unmet medical need for this aggressive form of lymphoma,” said Sharon Shacham, Karyopharm CEO. 

On Friday, Wedbush analyst David Nierengarten upgraded shares to outperform from neutral (PT $19) saying current levels offer an “attractive entry point” ahead of initial Phase 2b “Sadal” data next month. He also said “I believe selinexor will be approved in multiple myeloma on its Pdufa date of April 6 and looking to additional Phase 2b “Storm” data at the ASH conference . 

Karyopharm Announces Results of Clinical Studies Investigating Selinexor to be Presented at the European Hematology Association 2019 Annual MeetingGlobeNewswire | 05/16/2019

Karyopharm’s Founder Sharon Shacham, PhD, Receives NYIPLA Inventor of the Year AwardGlobeNewswire | 05/15/2019

Karyopharm Therapeutics Inc. (KPTI) CEO Dr. Michael Kauffman on Q1 2019 Results - Earnings Call TranscriptSeeking Alpha | 05/09/2019

Karyopharm Reports First Quarter 2019 Financial Results and Highlights Recent Company ProgressGlobeNewswire | 05/09/2019

Karyopharm to Participate in Upcoming Investor ConferencesGlobeNewswire | 05/08/2019

Karyopharm to Report First Quarter 2019 Financial Results on May 9, 2019GlobeNewswire | 05/02/2019

Karyopharm Therapeutics Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)GlobeNewswire | 05/01/2019